Jagsonpal Pharmaceuticals Limited

JAGSNPHARM

INE048B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 09:03:22 2024-04-25 am EDT			5-day change	1st Jan Change
333.4 ^INR	+3.96%		+3.16%	-14.28%

Mar. 08	Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®	CI
Feb. 02	Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes	CI

Jagsonpal Pharmaceuticals Limited Announces Board Changes

November 14, 2019 at 07:09 am EST

Jagsonpal Pharmaceuticals Limited announced the Appointment of Mr. Ashok Kumar Pati and Mr. Mammen Mathew as the Additional Non-Executive Independent Director on the Board w.e.f, 14‘ Day of November, 2019.

Latest news about Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®	Mar. 08	CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes	Feb. 02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 03	CI
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1	23-08-03	MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-23	CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23-05-23	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar.	23-03-30	CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer	23-02-13	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	22-12-31	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-09	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	22-07-16	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm cancelled the acquisition of 26% stake in Jagsonpal Pharmaceuticals Limited.	22-06-19	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Infinity Holdings to Acquire Controlling Stake in Jagsonpal Pharmaceuticals for $36 Million	22-02-22	MT
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others entered into a share purchase agreement to acquire 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar for INR 2.7 billion.	22-02-20	CI
Infinity Investment Management made an offer to acquire 26% stake in Jagsonpal Pharmaceuticals Limited for INR 1.6 billion.	22-02-20	CI
Jagsonpal Pharmaceuticals Limited Enters into an Agreement with Suvinys Developers Private Limited for Supply of Product Dydrogesterone	22-02-18	CI
Jagsonpal Pharmaceuticals Names New CFO	22-02-13	MT
Jagsonpal Pharmaceuticals Appoints New CFO	22-02-11	MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
Jagsonpal Pharmaceuticals CFO Resigns	22-02-01	MT

Chart Jagsonpal Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Companyâs therapy areas include gynecology, orthopedics, and others.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JAGSONPAL PHARMACEUTICALS LIMITED	-14.28%	102M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B